Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exicorilant plus enzalutamide in metastatic castration-resistant prostate cancer
2017-003287-12Phase 2Unknown
- Sponsor
- Corcept Therapeutics
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exicorilant in metastatic castration-resistant prostate cancer (mCRPC) and castration-resistant prostate cancer (CRPC), sponsored by Corcept Therapeutics. Primary endpoints: Maximum tolerated dose and/or biologically active dose, Safety and tolerability and 4 more. Status: unknown.
02
Drugs
exicorilant
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2017-003287-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003287-12.